Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients

gan Lasnon, Charline, Desmonts, Cédric, Quak, Elske, Gervais, Radj, Do, Pascal, Dubos-Arvis, Catherine, Aide, Nicolas
Cyhoeddwyd 2013

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer

gan Dumont, Delphine, Dô, Pascal, Lerouge, Delphine, Planchard, Gaëtane, Riffet, Marc, Dubos-Arvis, Catherine, Danhier, Serge, Gervais, Radj
Cyhoeddwyd yn Am J Case Rep (2017)

Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy

gan Le Baut, Guillaume, Guilloit, Jean-Marc, Leprince, Vincent, Ollivier, Yann, Dubos-Arvis, Catherine, Do, Pascal, Sutter, Jasmine, Loge, Ludovic, Gervais, Radj
Cyhoeddwyd yn J Gastrointest Oncol (2018)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

gan Auliac, Jean-Bernard, Dô, Pascal, Bayle, Sophie, Doubre, Hélène, Vinas, Florent, Letreut, Jacques, Falchero, Lionel, Hauss, Pierre Alexandre, Thomas, Pascal, Chouaid, Christos
Cyhoeddwyd yn Adv Ther (2019)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

gan Lesueur, Paul, Escande, Alexandre, Thariat, Juliette, Vauléon, Enora, Monnet, Isabelle, Cortot, Alexis, Lerouge, Delphine, Danhier, Serge, Dô, Pascal, Dubos‐Arvis, Catherine, Chouaïd, Christos, Gervais, Radj
Cyhoeddwyd yn Cancer Med (2018)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL stud...

gan Bennouna, Jaafar, Barlesi, Fabrice, Do, Pascal, Dumont, Patrick, Cadranel, Jacques, Debieuvre, Didier, Hilgers, Werner, Molinier, Olivier, Quoix, Elisabeth, Raimbourg, Judith, Langlais, Alexandra, Morin, Franck, Souquet, Pierre-Jean
Cyhoeddwyd yn ESMO Open (2018)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

gan Vergnenegre, Alain, Geier, Margaux, Guisier, Florian, Lamy, Regine, Comet, Bénédicte, Le Garff, Gwenaelle, Do, Pascal, Janicot, Henri, Morel, Hugues, Decroisette, Chantal, Andre, Michel, Falchero, Lionel, Paleiron, Nicolas, Monnet, Isabelle
Cyhoeddwyd yn Cancer Med (2019)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

gan Auliac, Jean-Bernard, Bayle, Sophie, Do, Pascal, Le Garff, Gwenaëlle, Roa, Magali, Falchero, Lionel, Huchot, Eric, Quéré, Gilles, Jeannin, Gaëlle, Métivier, Anne-Cécile, Hobeika, Joëlle, Guisier, Florian, Chouaid, Christos
Cyhoeddwyd yn Cancers (Basel) (2020)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy f...

gan Borget, Isabelle, Pérol, Maurice, Pérol, David, Lavolé, Armelle, Greillier, Laurent, Dô, Pascal, Westeel, Virginie, Crequit, Jacky, Léna, Hervé, Monnet, Isabelle, Le Caer, Hervé, Fournel, Pierre, Falchero, Lionel, Poudenx, Michel, Vaylet, Fabien, Chabaud, Sylvie, Vergnenegre, Alain, Zalcman, Gérard, Chouaïd, Christos
Cyhoeddwyd yn BMC Cancer (2014)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

gan Baldacci, Simon, Mazieres, Julien, Tomasini, Pascale, Girard, Nicolas, Guisier, Florian, Audigier-Valette, Clarisse, Monnet, Isabelle, Wislez, Marie, Pérol, Maurice, Dô, Pascal, Dansin, Eric, Leduc, Charlotte, Giroux Leprieur, Etienne, Moro-Sibilot, Denis, Tulasne, David, Kherrouche, Zoulika, Labreuche, Julien, Cortot, Alexis B.
Cyhoeddwyd yn Oncotarget (2017)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients

gan Cadranel, Jacques, Cortot, Alexis B., Lena, Hervé, Mennecier, Bertrand, Do, Pascal, Dansin, Eric, Mazieres, Julien, Chouaid, Christos, Perol, Maurice, Barlesi, Fabrice, Robinet, Gilles, Friard, Sylvie, Thiberville, Luc, Audigier-Valette, Clarisse, Vergnenegre, Alain, Westeel, Virginie, Slimane, Khemaies, Buturuga, Alexandru, Moro-Sibilot, Denis, Besse, Benjamin
Cyhoeddwyd yn ERJ Open Res (2018)

Utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab

gan Dupont, Benoît, Mariotte, Delphine, Dugué, Audrey E., Clarisse, Bénédicte, Grellard, Jean‐Michel, Babin, Emmanuel, Chauffert, Bruno, Dakpé, Stéphanie, Moldovan, Cristian, Bouhier‐Leporrier, Karine, Reimund, Jean‐Marie, Di Fiore, Frederic, Zanetta, Sylvie, Mailliez, Audrey, Do, Pascal, Peytier, Annie, Galais, Marie‐Pierre, Florescu, Carmen, Schott, Roland, Le Mauff, Brigitte, Gervais, Radj
Cyhoeddwyd yn Br J Clin Pharmacol (2016)